Niagen Bioscience, Inc. (NAGE)

In the past six months, Niagen Bioscience's stock has been impacted by several events. The company reported Q1 2026 results that exceeded consensus estimates, with total net sales increasing 3% to $31.5 million and net income climbing to $6.3 million. Niagen Bioscience launched a clinician-directed telehealth platform for Niagen Plus, offering at-home injection kits to eligible U.S. patients. The company added Olympia Pharmaceuticals to its 503B Compounding Partner Network, diversifying its supply chain and expanding Niagen Plus offerings. Niagen Bioscience collaborated with the U.S. Pharmacopeia (USP) to establish the first-ever USP monograph for nicotinamide riboside chloride (NRCl), setting a quality benchmark for the ingredient. The company expanded its Niagen Plus clinical channel through a partnership with OneSpaWorld, making Niagen IV available in over 80 Medi-Spa clinics on luxury cruise ships. Niagen Bioscience pilot-launched Niagen's Nanocloud, its first skincare topical product, with strong early demand. The company completed the sale of its Analytical Reference Standards and Services segment to LGC Standards in an all-cash transaction, streamlining operations. The board approved a $20 million increase in the company's share repurchase program. As of May 10, 2026, the stock has experienced a 6.26% decline in the past 30 days and a 32.96% decline year-to-date. Over the past 12 months, the stock has lost 50.4% of its value. Roth Capital lowered its price target on NAGE from $13 to $12 in May 2026.

The broader NAD+ supplement market, in which Niagen Bioscience operates, experiences seasonal demand. Demand for NAD+ supplements typically peaks in January, driven by New Year's health and wellness resolutions. Consistent buyer interest in wellness, longevity, and "biohacking" trends also contributes to repeat purchases and a strong fit for subscription models.

Niagen Bioscience, Inc. (NAGE), formerly ChromaDex Corporation, is a Los Angeles-based bioscience company founded in 1999 and publicly traded on NASDAQ as part of the Russell 2000 Index. Operating in the Healthcare sector, specifically Biotechnology & Medical Research, it focuses on NAD+ science and healthy-aging research. Its major products and services revolve around its patented nicotinamide riboside (NR) ingredient, branded as Niagen®, including Tru Niagen® dietary supplements, Niagen Plus™ pharmaceutical-grade formulations, Niagen® as an ingredient for other manufacturers, and Niagen's Nanocloud™ topical skincare product. The company divested its Analytical Reference Standards and Services segment in February 2026.

Niagen Bioscience's headquarters are in Los Angeles, California. Tru Niagen is distributed directly to consumers through its e-commerce platform, Amazon, other internet marketplaces, specialty retailers, and authorized healthcare practitioner resellers in the U.S. Niagen Plus IV and injectable products are available at hundreds of clinics nationwide, including iCRYO locations, and have expanded to over 80 Medi-Spa clinics on luxury cruise ships. The company also holds a global patent portfolio for its core ingredient.

Niagen Bioscience cultivates a strong brand reputation as a scientific authority and pioneer in NAD+ discoveries and healthy-aging research. The company emphasizes its commitment to peer-reviewed science, clinical trials, and a robust patent portfolio protecting its Niagen® ingredient. The establishment of an official USP monograph for nicotinamide riboside chloride, with Niagen® being compliant with this standard, reinforces the company's commitment to quality and sets an industry benchmark. The company proudly holds two distinct A2LA accreditations, demonstrating its adherence to rigorous laboratory operation standards. No specific negative events directly impacting the company's brand reputation in terms of product quality or scientific integrity were found in the past year.

Niagen Bioscience has a mix of institutional and individual owners. Approximately 15.41% of the stock is held by institutions, including BlackRock, Inc., and Vanguard Group Inc. Insiders hold about 9.39% of the company's stock, including Frank L Jaksch Jr and Robert N Fried.